KLRS (KLRS) reported D&A of $10K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

KLRS KLRS D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

AmgenAMGN

$1.12B-19.5%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

EyePoint, Inc. EYPT

$636K+28.0%

Ocular TherapeutixOCUL

$1.28M+30.8%

Kodiak Sciences IncKOD

$4.11M-10.7%

Other financials

Income statement

See full

Operating income-$11.8M-14.3%

Net income-$10.9M-6.5%

EPS (diluted)-$0.46+81.7%

Balance sheet

See full

Cash & equivalents$34.4M-65.9%

Total debt$1.4M—

Total equity$68.6M+7.3%

Total assets$109.8M+6.5%

Cash flow

See full

Operating cash flow-$11.6M-55.6%

CapEx$17.0K—

Free cash flow-$7.1M—

Valuation

See full

Market cap$96.83M+136%

Enterprise value$63.82M—

Returns & leverage

See full

Return on equity-66.6%—

Debt / equity0×—

Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is KLRS's D&A?: KLRS (KLRS) reported D&A of $10K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.